FDA Facility Issue May Delay Regeneron's EYLEA HD Launch
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.
/ 97 items
#NVO↓
Novo Nordisk Acquires Akero Therapeutics for $5.2 Billion, Securing Key MASH Treatment EFX
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.
Novo Nordisk Bets on Telehealth to Relaunch its Weight-Loss Dominance with "Wegovy-in-a-Pill"
Novo Nordisk is planning a strategic digital launch for its forthcoming obesity pill, targeting telehealth sites like Ro and WeightWatchers in early 2026 to recapture market share lost to rival Eli Lilly and combat the rise of copycat drugs.
GoodRx and Kroger Partner for Instant Drug Savings
GoodRx and Kroger launched RxSmartSaver at 2,200 pharmacies. Scan a code for instant discounts on brand drugs like Ozempic and Lantus.
European Drugmakers Surge: Pfizer's US Pricing Deal Offers a Tariff Blueprint
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
Morgan Stanley Sees Downside to 2026-27 Consensus for Novo Amid Competition and Patent Risks
Novo Nordisk was downgraded because key drug sales (Ozempic/Wegovy) are slowing. Competition and future patent loss are hurting the stock.